New hope for kidney transplant patients: cholesterol drug evolocumab shows promise

NCT ID NCT04608474

Completed Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested the drug evolocumab (Repatha) in 81 kidney transplant recipients with high cholesterol. The goal was to see if it could safely lower cholesterol levels, since standard statin drugs often cause side effects in these patients. The results could lead to a better way to manage heart disease risk after a kidney transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evolocumab (Repatha)
What this could lead to: If successful, this could provide a safer cholesterol-lowering option for kidney transplant patients, reducing their heart disease risk.
What could go wrong: This is a small pilot study with only 81 participants, so results may not apply to everyone. The drug's long-term safety in transplant recipients is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPIDEMIAS

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.